StemCell Therapy

DUBLIN, Nov. 24, 2020 /PRNewswire/ -- The "Companion Diagnostic Markets - the Future of Diagnostics, by Funding Source and Application with Customized Forecasting/Analysis, COVID-19 Updates, and Executive and Consultant Guides 2021-2025" report has been added to ResearchAndMarkets.com's offering.

Companion Diagnostics are poised to revolutionize the diagnostics industry. The market is finally moving out of the lab and into the clinic. Oncology, especially immune-oncology is leading the way. And the FDA is holding the door open for this diagnostic technology of the future. But COVID-19 is impacting healthcare treatment everywhere and lowering demand for specialized cancer testing. Find out the latest outlook for this important market.

Will Personalized Companion Diagnostics become the norm for diagnostics?

Learn all about how diagnostic players are jockeying for position with their pharmaceutical counterparts and creating new and significant business opportunities. And some players are already taking the lead. It is a dynamic market situation with enormous opportunity. Diagnostic companies are trying to back the right horse. The science is racing forward. And the cost of molecular diagnostics continues to fall.

This report provides data that analysts and planners can use. Hundreds of pages of information including a complete list of Current 2020 United States Medicare Fee Payment Schedules to help understand test pricing in detail. Forecast demand for new testing regimes or technologies. Make research investment decisions. Existing laboratories and hospitals can use the information directly to forecast and plan for clinical facilities growth.

The report includes detailed breakouts for 18 Countries and 4 Regions.

Companion Diagnostic Market - Strategic Situation Analysis

Key Topics Covered:

1. Introduction and Market Definition

2. Market Overview 2.1 Players in a Dynamic Market 2.1.1 Academic Research Lab 2.1.2 Diagnostic Test Developer2.1.3 Instrumentation Supplier 2.1.4 Distributor and Reagent Supplier 2.1.5 Independent Testing Lab2.1.6 Public National/regional lab 2.1.7 Hospital lab 2.1.8 Physician Office Labs 2.1.9 Audit Body 2.1.10 Certification Body2.2 Personalized Medicine and Companion Diagnostics 2.2.1 Basics 2.2.2 Method 2.2.3 Disease risk assessment 2.2.4 Applications 2.2.5 Diagnosis and intervention 2.2.5.1 Companion Diagnostics 2.2.6 Drug development and usage 2.2.7 Respiratory proteomics 2.2.8 Cancer genomics 2.2.9 Population screening 2.2.10 Challenges 2.2.11 Regulatory oversight 2.2.12 Intellectual property rights 2.2.13 Reimbursement policies2.2.14 Patient privacy and confidentiality 2.3 Chromosomes, Genes and Epigenetics 2.3.1 Chromosomes2.3.2 Genes 2.3.3 Epigenetics 2.4 Cancer Genes 2.4.1 Germline vs Somatic 2.4.2 Changing Clinical Role 2.5 Structure of Industry Plays a Part 2.5.1 New Pharmaceutical Funding Market 2.5.2 Economies of Scale2.5.2.1 Hospital vs. Central Lab 2.5.3 Physician Office Labs 2.5.4 Physicians and POCT

3. Market Trends3.1 Factors Driving Growth3.1.1 Level of Care 3.1.2 Immuno-oncology 3.1.3 Liability3.1.4 Aging Population3.2 Factors Limiting Growth3.2.1 State of knowledge3.2.2 Genetic Blizzard. 3.2.3 Protocol Resistance3.2.4 Regulation and coverage 3.3 Instrumentation and Automation 3.3.1 Instruments Key to Market Share 3.3.2 Bioinformatics Plays a Role 3.4 Diagnostic Technology Development3.4.1 Next Generation Sequencing Fuels a Revolution. 3.4.2 Single Cell Genomics Changes the Picture 3.4.3 Pharmacogenomics Blurs Diagnosis and Treatment3.4.4 CGES Testing, A Brave New World 3.4.5 Biochips/Giant magneto resistance based assay

4. Companion Diagnostics Recent Developments 4.1 Recent Developments - Importance and How to Use This Section 4.1.1 Importance of These Developments 4.1.2 How to Use This Section

5. Profiles of Key Players

6. The Global Market for Companion Diagnostics6.1 Global Market Overview by Country6.1.1 Table - Global Market by Country6.1.2 Chart - Global Market by Country 6.2 Global Market by Application - Overview 6.2.1 Table - Global Market by Application 6.2.2 Chart - Global Market by Application - Base/Final Year Comparison 6.2.3 Chart - Global Market by Application - Base Year 6.2.4 Chart - Global Market by Application - Final Year 6.2.5 Chart - Global Market by Application - Share by Year6.3 Global Market Funding Source - Overview 6.3.1 Table - Global Market by Funding Source 6.3.2 Chart - Global Market Funding Source - Base/Final Year Comparison 6.3.3 Chart - Global Market Funding Source - Base Year 6.3.4 Chart - Global Market Funding Source - Final Year6.3.5 Chart - Global Market Funding Source - Share by Year

7. Global Companion Diagnostic Markets - By Application 7.1 Oncology 7.1.1 Table Oncology - by Country 7.1.2 Chart - Oncology Growth7.2 Neurology 7.2.1 Table Neurology - by Country 7.2.2 Chart - Neurology Growth 7.3 Cardiology 7.3.1 Table Cardiology - by Country 7.3.2 Chart - Cardiology Growth7.4 Other Application7.4.1 Table Other Application - by Country7.4.2 Chart - Other Application Growth

8. Global Companion Diagnostic Markets - Funding Source8.1 Global Market Pharmaceutical 8.1.1 Table Pharmaceutical - by Country8.1.2 Chart - Pharmaceutical Growth 8.2 Global Market Venture 8.2.1 Table Venture - by Country8.2.2 Chart - Venture Growth 8.3 Global Market Clinical 8.3.1 Table Clinical - by Country8.3.2 Chart - Clinical Growth 8.4 Global Market Other Funding 8.4.1 Table Other Funding - by Country 8.4.2 Chart - Other Funding Growth

For more information about this report visit https://www.researchandmarkets.com/r/wci97x

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager [emailprotected]

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

Original post:
Outlook on the Companion Diagnostic Global Market to 2025 with COVID-19 Updates - PRNewswire

This entry was posted on November 24, 2020 at 9:55 am and is filed under Personalized Medicine. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |